Option chain shows key data for INDVR Brands's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for INDVR Brands.

INDVR Brands (OTC:CAAOF) Stock, Option Chain

INDVR Brands Inc is focused on providing personnel and management resources as well as infrastructure and equipment for use in the production, cultivation and dispensary operations of licensed cannabis businesses. It provides support services to licensed cannabis businesses.

News

Intraday Update

Markets

Movers

Trading Ideas

ABCE

ACST

AIPUY

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ALTM

AMADF

AMCX

ANLDF

ANZFF

APTS

APVO

AQARF

ARCH

ASBRF

ASIX

ATRO

ATROB

ATUSF

AWCMY

AXION VENTURES INC by Axion Ventures Inc.

AXNVF

BBDO

BBSI

BCII

BFCH

BKUCF

BMMJ

BORR

BPAQF

BPMP

BRID

BRRAY

BUHPF

CANNABIS ONE HLDGS INC by Cannabis One Holdings Inc.

CAAOF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CCDBF

CCLLF

CCLP

CDEV

CEQP

CHOOF

CHRRF

CJPRY

CJREF

CLDT

CLVLY

CNDT

CNXM

COKE

CRON

CWBHF

CWYUF

CYBL

DAKT

DCIX

DGEAF

DLNDY

DLTH

DNKLY

DRTT

EARS

EBIX

ECAOF

EMERALD HEALTH THERAPUTCS by Emerald Health Therapeutics Inc.

EMHTF

ENBL

ENLC

ENOB

FRONTERA ENERGY CORP ORD by Frontera Energy Corp

FECCF

FLNG

Stocks That Hit 52-Week Lows On Wednesday

Cannabis

Exclusives

CSE:CBIS

A Look At The Cannabis One–ONE Cannabis Merger: &#39;Truly A Combination Of Equals&#39;

Movers & Shakers

General

AEMD

AFOM

AKER

ALRM

APDN

AREX

ASPCF

AUSAF

AXLA

BCEI

BLGVF

BNKPF

BRTX

BRVVF

BUDZ

BVTK

CADMF

CCORF

CGIX

CIRX

CNAB

CNPOF

CRVYF

CRXPF

CRZO

CTRA

CVEO

CVSI

CYDVF

DSWL

DYNT

ENZN

ETRN

EUROPEAN ELECTRIC METALS by European Electric Metals Inc.

EVXXF

EWLL

EXPE

EXTN

EZPW

FUTURE FARM TECHNOLOGIES by Future Farm Technologies Inc.

FFRMF

FOSL

FPRX

GBHL

GGBXF

GGTTF

GHSI

GLDFF

GLOG

GLOP

GRJVF

GRNQ

GRTD

GTCH

GTLS

GYNAF

HEXO

HRTFF

IIVI

ILUS

IMHC

INAP

INLB

INQD

IONKF

IVITF

JAGX

JWCAF

KCLI

KGET

KLXE

KPOC

LBRT

AMERICAN LITHIUM CORP ORD by American Lithium Corp.

LIACF

LIQT

LKSD

LQSIF

Stocks That Hit 52-Week Lows On Tuesday

INDVR Brands Inc

Seagate Technology Holdings PLC&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>)&nbsp;shares are trading higher premarket on Wednesday. Yesterday, the company reported&nbsp;second-quarter&nbsp;FY25 revenue of&nbsp;$2.33 billion,&nbsp;beating<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43113660/seagate-technology-reports-fiscal-second-quarter-2025-financial-results" rel="noreferrer noopener"> the consensus of&nbsp;$1.56 billion</a>.
Adjusted gross margin rose to&nbsp;35.5%&nbsp;from&nbsp;23.6%&nbsp;a year ago quarter.
Adjusted operating margin escalated to 23.1% from 8.2% in the prior-year quarter. Adjusted EPS of $2.03 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">beat the consensus of $1.88</a>.
See Also: <a href="https://www.benzinga.com/25/01/43124975/why-gillette-parent-procter-gambles-stock-is-rising-today">Gillette Parent Procter &amp; Gamble Navigates Commodity And Forex Challenges</a>
In Q2, the company generated an operating cash flow of $221 million plus free cash flow of $150 million.
The company returned&nbsp;$148&nbsp;million&nbsp;to shareholders via its quarterly dividend. As of end of the second quarter, cash and cash equivalents totaled&nbsp;$1.2 billion.
Dividend: The board of directors declared a cash dividend of 72 cents per share. The dividend is payable on April 2, to shareholders of record as of March 19, 2025.
Outlook: Seagate expects third-quarter adjusted EPS of $1.70, against the consensus of $1.71. It also expects revenue of $2.1 billion versus the <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">$2.2 billion estimate</a>.
Seagate is &#8220;advancing&#8221; the company&#8217;s technology roadmap to meet customers&#8217; growing need for AI storage solutions, CEO Dave Mosley said.
&#8221;We began ramping HAMR-based Mozaic products to our lead cloud customer in the December quarter and are already sampling in capacities of up to 36 terabytes. Looking ahead, we believe Seagate is in a great position to deliver profitable growth in fiscal 2025,&#8221; he added.
Investors can gain exposure to the stock via&nbsp;StockSnips AI-Powered Sentiment US All Cap ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEWZ#NASDAQ">NEWZ</a>) and&nbsp;Affinity World Leaders Equity ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/WLDR#BATS">WLDR</a>).
Price Action: STX shares are up 6.67% at $108 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/43122855" target="_blank" rel="noreferrer noopener">Trump&#8217;s Plan To Revoke&nbsp;$7,500&nbsp;EV Tax Credit Is A &#8216;Huge&#8217; Negative For Tesla, Says Gary Black, Downplays Impact On Rivals</a></li>
</ul>
Image: Shutterstock

Earnings

Equities

Large Cap

Guidance

Dividends

Tech

NEWZ

WLDR

Seagate Ramps Up Technology For AI, Delivers Profitable Growth In Q2

Management expects 2024 fourth quarter revenue of approximately $3.0 million and full year 2024 of approximately $8.6 million, representing growth year-over-year of over 100% for the third consecutive year
Management expects to generate at least $13 million in revenue for 2025 and to achieve positive cash flow from operations during the year
LANGHORNE, Pa., Jan. 22, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today issued a letter to its shareholders from Chief Executive Officer, Adam Levy, and is providing guidance for 2024 and 2025.
Dear Fellow NEXGEL Shareholders,
2024 was a transformative year for NEXGEL and I have high expectations for 2025. I would like to share a brief recap of our accomplishments over the past year, the current status of our business units, and several upcoming growth levers for the business.
Our revenue expectation for the fourth quarter 2024 is approximately $3.0 million, bringing total revenue for 2024 to approximately $8.6 million, representing growth year-over-year of over 100% for the third consecutive year. Looking into 2025, we expect to generate at least $13 million in full year revenue and to be cash flow positive from operations during the year.
NEXGEL is focused on three core segments which we believe will drive significant shareholder value: (i) contract manufacturing and white label, (ii) consumer products and (iii) aspirational medical device development. These areas are key to our strategic growth and long-term success of the business.
Contract manufacturing and white label played a pivotal role in our growth in 2024 led by increased demand from existing customers and the successful onboarding of several new global corporations. This segment continues to be a major driver of our expansion and success.
Additionally, of our two new large international customers, one began generating revenue as expected in the fourth quarter of 2024 and the other is expected to begin generating revenue this quarter. Looking ahead, we have a healthy pipeline of potential new customers for 2025, including Innovative Optics. We anticipate the publication of their study of the carcinogenic plume generated by laser hair removal, as well as the effectiveness of our pads in suppressing that plume, later this quarter.
Consumer products across our entire portfolio saw remarkable expansion in 2024 driven by the continued success of our Medagel brand, the acquisitions of Kenkoderm and Silly George and our strategic partnership with Stada. This year Medagel will expand its product line with the anticipated launch of several new offerings, including a SilverSeal wound and burn kit and our moist burn pads. Kenkoderm continues to show growth, with plans to launch new products for an additional indication in the third quarter of this year.
After acquiring Silly George in May of 2024, we quickly integrated the brand onto our platform. As a result, we saw growth from its initial $2 million annual revenue run rate to over $5 million and believe the upward trajectory will continue. We have several exciting new products we anticipate launching in 2025, including a beauty under-eye patch that utilizes our own hydrogel technology.
Lastly, our partnership with Stada is progressing well and the first product, Histasolv, is exceeding projections. We are preparing for two additional product launches from Stada which we expect to occur during the second half of 2025.

NXGL

NEXGEL Expects Q4 2024 Revenue At $3M; FY24 Total Revenue $8.6M; Predicts $13M Revenue For 2025, Cash Flow Positive; Highlights Growth In Contract Manufacturing, Consumer Products

Canoo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) shares fell some 72% to 37 cents during Tuesday&#8217;s session after the company announced it filed for <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43098271/canoo-files-bankruptcy-stock-falls-nasa-walmart-dod-usps">Chapter 7 bankruptcy</a>.
What To Know: The announcement marks the end of Canoo&#8217;s operations. The filing, submitted on January 17 in the U.S. Bankruptcy Court for the District of Delaware, includes Canoo and its key subsidiaries, such as Canoo Technologies Inc. and Canoo Manufacturing LLC.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43113872/rivian-lucid-shares-are-falling-today-whats-going-on">Rivian, Lucid Shares Are Falling Today: What&#8217;s Going On?</a>
Under Chapter 7, a court-appointed trustee will oversee the liquidation of Canoo's assets to settle its liabilities. This process eliminates the authority of the company's Board of Directors and executive leadership. All claims will be addressed according to bankruptcy laws.
Once considered a <a href="https://www.benzinga.com/news/21/12/24644913/why-canoo-shares-are-climbing-higher-today">promising player</a> in the EV market, Canoo faced mounting financial challenges, including cash flow issues and delays in production. 
The liquidation underscores the difficulties startups face in the competitive electric vehicle industry, as they contend with high costs and intense competition.
Read Also: <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/43113169/trumps-ev-rollback-might-shake-up-etfs-winners-losers-and-teslas-unique-role-in-shifting-market">Trump&#8217;s EV Rollback Might Shake-Up ETFs: Winners, Losers And Tesla&#8217;s Unique Role In Shifting Market</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, GOEV has a 52-week high of $102.07 and a 52-week low of $0.32.

GOEV

Why Canoo (GOEV) Stock Fell 72% Tuesday

Craig-Hallum analyst Chase Knickerbocker maintains Ironwood Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRWD#NASDAQ">IRWD</a>) with a Buy and lowers the price target from $10 to $8.

Price Target

Analyst Ratings

IRWD

Craig-Hallum Maintains Buy on Ironwood Pharmaceuticals, Lowers Price Target to $8

Trial taking place at <a href="https://www.seha.ae/hospital-detail/1">Sheikh Khalifa Medical City</a>, a flagship tertiary hospital in the United Arab Emirates
POC data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for MVID
Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome with intestinal failure (SBS-IF)
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / January 22, 2025 / <a href="https://pr.report/66fk">Jaguar Health, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/66fm">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/66fn">Napo Therapeutics</a> today announced that the first patient has been dosed in the independent investigator-initiated POC trial of crofelemer, Jaguar's novel plant-based anti-diarrheal prescription drug, for the rare disease indication of MVID in pediatric patients. POC data generated from this study potentially in the first half of 2025 could lead to reimbursed early patient access to crofelemer for this indication in certain European countries.
The trial will also include pediatric patients with SBS-IF. It is being conducted by Dr. Mohamad Miqdady, a recognized leader in pediatric gastroenterology who is the Division Chief of the Pediatric Gastroenterology, Hepatology &amp; Nutrition Division at <a href="https://pr.report/66fo">Sheikh Khalifa Medical City</a> (SKMC), a flagship tertiary hospital in the UAE and the largest teaching medical center in Abu Dhabi.

Biotech

Jaguar Health Announces First Patient Dosed In UAE POC Trial For Crofelemer In Pediatric MVID; Potential For Early Access In Europe By H1 2025; Drug Holds Orphan Designation For MVID And SBS-IF By FDA And EMA

First Community (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCCO#NASDAQ">FCCO</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.49 by 12.24 percent. This is a 27.91 percent increase over earnings of $0.43 per share from the same period last year.

Earnings Beats

FCCO

First Community Q4 EPS $0.55 Beats $0.49 Estimate

President Donald Trump's repeal of President Joe Biden's executive order targeting 50% electric vehicle (EV) adoption by 2030 sent shares of Blink Charging Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) sliding 5.4% to $1.39 Tuesday. The stock is otherwise flat Wednesday pre-market.
The <a href="https://www.benzinga.com/etfs/sector-etfs/25/01/43113169/trumps-ev-rollback-might-shake-up-etfs-winners-losers-and-teslas-unique-role-in-shifting-market">policy reversal</a> raises concerns about reduced federal EV subsidies, relaxed emissions standards and limits on state-level emissions waivers, all of which could slow EV adoption in the U.S.
Read Also: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/01/42985694/chargepoint-outpaces-tesla-in-ev-network-market-share-but-jpmorgan-stays-cautious">ChargePoint Outpaces Tesla In EV Network Market Share, But JPMorgan Stays Cautious</a>
What Else: As a key player in EV charging infrastructure, Blink faces significant headwinds if EV sales falter. A reduction in federal tax credits could discourage EV purchases, directly impacting demand for charging networks. 
Lower consumer interest in EVs might also delay infrastructure expansion and revenue growth for companies like Blink.
While some states may counter federal rollbacks with pro-EV initiatives, uncertainty looms over Blink's near-term outlook. Increased volatility for EV-dependent stocks may happen in the near-term but global electrification trends could serve as a potential long-term tailwind.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/01/43116755/trumps-plan-to-end-7500-ev-tax-credits-could-be-devastating-for-telsa-rivals-poll-says-could-be-bullish-for-elon-musks-company">Trump&#8217;s Plan To End $7,500 EV Tax Credits Could Be &#8216;Devastating&#8217; For Telsa Rivals, Poll Says Could Be Bullish For Elon Musk&#8217;s Company</a>
<h2 class="wp-block-heading">Should I Sell My BLNK Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Shares of Blink Charging have lost 45.06% year to date. This compares to the average annual return of -59.26%, meaning the stock has outperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity. 
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
BLNK has a 52-week high of $3.75 and a 52-week low of $1.31.

BLNK

Why Blink Charging (BLNK) Stock Is Volatile

Comments

INDVR Brands

INDVR Brands (CAAOF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga